Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4058

Sort by

Sort Order Select

Journal Articles

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition

Blood (2026) 147 (2): 209–214.

https://doi.org/10.1182/blood.2025031086

Published: 2026

Includes: Supplemental data

Journal Articles

Drug development in MZL: caring for the forgotten child

Catherine Thieblemont, Sylvain Carras, Côme Bommier

Blood (2026) 147 (2): 127–137.

https://doi.org/10.1182/blood.2024028270

Published: 2026

Journal Articles

Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study

Blood (2026) 147 (2): 138–163.

https://doi.org/10.1182/blood.2025029640

Published: 2026

Includes: Supplemental data

Journal Articles

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han, Paola Ghione, Imran A Nizamuddin, Jahanzaib Khwaja, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J. Cherng, Seda S. Tolu, Nina D. Wagner-Johnston, Thomas A. Ollila, Natalie S. Grover, Jean L Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S. Wallace, Manali Kamdar, Rita Tavarozzi, Alexey V Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M Rhodes, Anca Prica, Andrea Kuhnl, Adrian Matthew Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima El-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Firas Baidoun Firas, Sarah Monick, Iris Margalit Trutzer, Jones Can, Amy A Ayers, Jacopo Calabrese De Feo, John Sharp, Nilanjan Ghosh, Rachel Treitman, Avyakta Kallam, Izel Okcu, Chathuri Abeyakoon, William Hann, Aisling Barrett, Vismay Deshani, Brad S Kahl, Julio C. Chavez, Adam J. Olszewski, Kate Cwynarski

Blood blood.2025031455.

https://doi.org/10.1182/blood.2025031455

Published: 2026

Includes: Supplemental data

Journal Articles

Tissue transglutaminase drives fibrin β-chain cross-linking: a novel fibrin modification observed in patients with trauma

Nana Kwame Kwabi Boateng, Riley Wimberley, Jacob Rose, Angelo D’Alessandro, Mitchell Cohen, Ernest Moore, Lauren Schmitt, Lauren Poole, James Luyendyk, Kirk Hansen

Blood (2026) 147 (1): 87–92.

https://doi.org/10.1182/blood.2025029458

Published: 2026

Includes: Supplemental data

Journal Articles

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

Blood (2026) 147 (1): 24–34.

https://doi.org/10.1182/blood.2024027009

Published: 2026

Includes: Supplemental data

Journal Articles

Measurable residual disease intervention in AML: a new therapeutic horizon

Andrew H. Wei, Harry J. Iland, Courtney D. DiNardo, John Reynolds

Blood (2026) 147 (1): 13–23.

https://doi.org/10.1182/blood.2025029010

Published: 2026

Journal Articles

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood blood.2025030190.

https://doi.org/10.1182/blood.2025030190

Published: 2025

Includes: Supplemental data

Journal Articles

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

Blood (2025) 146 (26): 3163–3174.

https://doi.org/10.1182/blood.2025029532

Published: 2025

Includes: Supplemental data

Journal Articles

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Blood (2025) 146 (26): 3153–3162.

https://doi.org/10.1182/blood.2025028550

Published: 2025

Includes: Supplemental data

Journal Articles

Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?

Christian P. Jaworek, Paul J. Bröckelmann

Blood (2025) 146 (26): 3145–3152.

https://doi.org/10.1182/blood.2025029935

Published: 2025

Journal Articles

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL

Manon Delafoy, Mickaël F. Bonnet, Etienne Lengliné, Agata Cieslak, Aurore Touzart, Estelle Balducci, Mathieu Simonin, Véronique Lhéritier, Marie Emilie Dourthe, Benoît Heid-Picard, Sylvain Latour, Hervé Dombret, Philippe Rousselot, André Baruchel, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi

Blood (2025) 146 (25): 3036–3049.

https://doi.org/10.1182/blood.2025030161

Published: 2025

Includes: Supplemental data

Journal Articles

Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients

Stephanie T. Isaac, David C. Bishop, Fahad Shaikh, Kenneth Micklethwaite, David J. Gottlieb, Emily Blyth

Blood (2025) 146 (25): 3124–3128.

https://doi.org/10.1182/blood.2025029057

Published: 2025

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood (2025) 146 (25): 3050–3058.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

Andy Itsara, Victoria M. Rogness, Laura Samples, Constance M. Yuan, Hao-Wei Wang, Inhye E. Ahn, Mohammed Z.H. Farooqui, Xin Tian, Clare Sun, Emily Tomasulo, Susan Soto, Jeanine Superata, Larisa Bezkorovaynaya, Thomas E. Hughes, Pia K. Nierman, Adrian Wiestner

Blood blood.2025029971.

https://doi.org/10.1182/blood.2025029971

Published: 2025

Includes: Supplemental data

Journal Articles

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Blood blood.2025029210.

https://doi.org/10.1182/blood.2025029210

Published: 2025

Includes: Supplemental data

Journal Articles

Methylation-based lineage tracing in cancer

Jiaoyi Chen, Benson Z Wu, Federico Gaiti

Blood blood.2025028196.

https://doi.org/10.1182/blood.2024028196

Published: 2025

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Blood (2025) 146 (24): 2902–2913.

https://doi.org/10.1182/blood.2025029360

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A/B With Inhibitors: Results from the Phase 3 BASIS Trial

Davide Matino, Suchitra Acharya, Carrie Turich Taylor, Pengling Sun, Delphine Agathon, Sangeeta Raje, Travis Gould, Andrew Palladino, Johnny Mahlangu

Blood blood.2025031065.

https://doi.org/10.1182/blood.2025031065

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition

Drug development in MZL: caring for the forgotten child

Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

Tissue transglutaminase drives fibrin β-chain cross-linking: a novel fibrin modification observed in patients with trauma

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

Measurable residual disease intervention in AML: a new therapeutic horizon

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL

Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Methylation-based lineage tracing in cancer

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A/B With Inhibitors: Results from the Phase 3 BASIS Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only